Print version | PDF version | Send article | RSS feed

Quotient Bioresearch acquires radiochemical custom synthesis operations from GE Healthcare

Major investment in new radiochemicals facility to be located in Cardiff, Wales

30 Jun 2009 - Quotient Bioresearch Limited announced that it has reached an agreement to acquire Amersham Radiolabelling Services, the radiochemical custom synthesis operations of GE Healthcare. This represents Quotient’s seventh acquisition since its formation in early 2007.
 
According to the company, this acquisition reinforces Quotient’s commitment to providing a seamless "synthesis to clinical study report” capability to pharmaceutical and biotechnology clients engaged in studies containing radiolabelled compounds. This integrated service will simplify the procurement of regulatory and non-regulatory studies, resulting in shorter development times and associated efficiencies.
 
In support of the acquisition of Amersham Radiolabelling Services, Quotient plans to invest up to £15 million in a new state-of-the-art-laboratory in Cardiff. Completion of this new facility is timed to coincide with GE Healthcare ending its radiolabelling operations at the end of March 2010, thus minimizing any impact on customers. Approximately 75 Amersham Radiolabelling Services scientific and commercial staff will transfer to Quotient.
 
To ensure continuity of service to customers, the transfer of operations and staff will take place in three stages. From today the global sales operations will transfer to Quotient, with the tritium and carbon-14 radiolabelling services transferring to Quotient by the end of 2009 and March 2010 respectively.